CDEK
← All drugs Report issue

fosinopril

Trade name: monopril

Small moleculeapproved

Approved

May 16, 1991

Fosinopril is a phosphinic acid-containing ester prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly hydrolyzed to fosinoprilat, its principle active metabolite. Fosinoprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Fosinopril may be used to treat mild to moderate hypertension, as an adjunct in the treatment of congestive heart failure, and to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy. — NCATS

Clinical trial activity

13 trials · 22 clinical orgs · 18 marketing orgs

Phase 1
0
Phase 2
3
Phase 3
1
Phase 4
4

Earliest trial started Apr 1, 1998 (NCT03073018)

Timeline

1990s

  1. May 16, 1991

    Earliest FDA Approval

  2. Jan 1, 1998

    Earliest Phase 3 Sponsor(trial)

2000s

  1. Jan 1, 2002

    Earliest Phase 2 Sponsor(trial)

  2. Nov 25, 2003

    Teva — Marketing Organization

  3. Apr 23, 2004

    Ranbaxy — Marketing Organization

  4. Apr 23, 2004

    Upsher-Smith Laboratories — Marketing Organization

  5. Apr 23, 2004

    Chartwell Pharmaceuticals — Marketing Organization

  6. Oct 15, 2004

    Actavis — Marketing Organization

  7. Dec 3, 2004

    Ani Pharmaceuticals — Marketing Organization

  8. Dec 17, 2004

    Sun Pharmaceuticals — Marketing Organization

  9. Dec 23, 2004

    Watson Pharmaceuticals — Marketing Organization

  10. Apr 20, 2005

    Invagen Pharms — Marketing Organization

  11. May 17, 2005

    Apotex — Marketing Organization

  12. Sep 28, 2005

    Sandoz — Marketing Organization

  13. Sep 28, 2005

    Novartis — Marketing Organization

  14. Aug 14, 2006

    Mylan — Marketing Organization

  15. Jul 9, 2009

    Aurobindo Pharma — Marketing Organization

2010s

  1. Sep 17, 2010

    Emcure — Marketing Organization

  2. Sep 17, 2010

    Avet Lifesciences — Marketing Organization

  3. Aug 29, 2016

    Prinston Inc — Marketing Organization

Indications

Approved for

Studied for

Mechanism of action

Combination products

Approval history

  • approvedMay 16, 1991

Chemistry & pharmacology

Loading structure…

SMILES

CCC(=O)O[C@@H](O[P@](=O)(CCCCc1ccccc1)CC(=O)N1C[C@H](C2CCCCC2)C[C@H]1C(=O)O)C(C)C
Mol. weight
563.67 g/mol
Lipinski Ro5
2 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Oral
Availability
Prescription Only

Oral

Yes

Parenteral

No

Topical

No

Black box warningProdrug

Sources

Also known as

  • (2s,4s)-4-cyclohexyl-1-[2-[(2-methyl-1-propanoyloxypropoxy)-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid
  • (2s,4s)-4-cyclohexyl-1-[2-[(2-methyl-1-propanoyloxypropoxy)-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid
  • (2s,4s)-4-cyclohexyl-1-{2-[(2-methyl-1-propionyloxy-propoxy)-(4-phenyl-butyl)-phosphinoyl]-acetyl}-pyrrolidine-2-carboxylic acid
  • (2s,4s)-4-cyclohexyl-1-{2-[(2-methyl-1-propionyloxy-propoxy)-(4-phenyl-butyl)-phosphinoyl]-acetyl}-pyrrolidine-2-carboxylic acid
  • fosenopril
  • fosenopril sodium
  • fosenopril sodium
  • fosinapril
  • fosinopril
  • fosinopril
  • fosinopril
  • fosinopril
  • fosinopril
  • fosinopril
  • fosinopril
  • fosinopril
  • fosinopril
  • fosinopril
  • fosinoprilat
  • fosinopril sodium
  • fosinopril sodium
  • fosinopril sodium
  • fosinopril sodium
  • fosinopril sodium
  • fositens
  • fositens
  • fozitec
  • fozitec
  • fozitec
  • monopril
  • monopril
  • monopril
  • (s)-4-cyclohexyl-1-{2-[(2-methyl-1-propionyloxy-propoxy)-(4-phenyl-butyl)-phosphinoyl]-acetyl}-pyrrolidine-2-carboxylic acid
  • (s)-4-cyclohexyl-1-{2-[(2-methyl-1-propionyloxy-propoxy)-(4-phenyl-butyl)-phosphinoyl]-acetyl}-pyrrolidine-2-carboxylic acid
  • sq-28555
  • sq-28555
  • staril
  • staril

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT02817360Phase 4Feb 1, 2016Medical University of Vienna, University of Vienna
NCT02646397Phase 4Feb 1, 2016Anhui College of Traditional Chinese Medicine, Dalian Medical University, Jiao Tong University, Second Military Medical University, Sichuan University, Southeast University, Zhejiang University, Zhengzhou University
NCT01669434Phase 4Jun 1, 2015University of Nebraska
NCT01014338Phase 4Oct 1, 2009Medical Research Council, University of London
NCT00315016Phase 2Jan 1, 2007Radboud University
NCT01342614N/AMay 1, 2006Peking University
NCT00565396N/ASep 1, 2004Jiao Tong University, Shanghai Municipal Health Bureau
NCT00778713N/AMar 1, 2003Ranbaxy
NCT00777972N/AMar 1, 2003Ranbaxy
NCT00776672N/AOct 1, 2002Ranbaxy
NCT00776334N/AOct 1, 2002Ranbaxy
NCT00051389Phase 2Feb 1, 2002National Heart, Lung, and Blood Institute (NHLBI), Wake Forest University
NCT03073018Phase 3Apr 1, 1998Dutch Kidney Foundation, Netherlands Heart Foundation, University of Groningen
Showing 13 of 13 trials
Page 1 / 1

Organizations

Research & Development (22)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
RanbaxyFor profit4412002
Jiao Tong UniversityAcademic/Hospital2022004
Anhui College of Traditional Chinese MedicineAcademic/Hospital1012016
Dalian Medical UniversityAcademic/Hospital1012016
Dutch Kidney FoundationAcademic/Hospital1011998
Medical Research CouncilGovernment1012009
Medical University of ViennaAcademic/Hospital1112016
National Heart, Lung, and Blood Institute (NHLBI)Government1112002
Netherlands Heart FoundationAcademic/Hospital1011998
Peking UniversityAcademic/Hospital1112006
Radboud UniversityAcademic/Hospital1112007
Second Military Medical UniversityGovernment1112016
Shanghai Municipal Health BureauGovernment1112004
Sichuan UniversityAcademic/Hospital1012016
Southeast UniversityAcademic/Hospital1012016
University of GroningenAcademic/Hospital1111998
University of LondonAcademic/Hospital1112009
University of NebraskaAcademic/Hospital1112015
University of ViennaAcademic/Hospital1012016
Wake Forest UniversityAcademic/Hospital1012002
22 organizations
Page 1 / 2

Marketing (22)

OrganizationOrg typeRelationshipDate
ActavisFor profitMKTGOct 15, 2004
Ani PharmaceuticalsFor profitSYNDec 3, 2004
Ani PharmaceuticalsFor profitMKTGDec 3, 2004
ApotexFor profitMKTGMay 17, 2005
ApotexFor profitSYNMay 17, 2005
Aurobindo PharmaFor profitMKTGJul 9, 2009
Aurobindo PharmaFor profitSYNMar 30, 2011
Avet LifesciencesFor profitMKTGSep 17, 2010
Bristol-Myers SquibbFor profitNDA—
Bristol-Myers SquibbFor profitSYNMay 16, 1991
Chartwell PharmaceuticalsFor profitMKTGApr 23, 2004
EmcureFor profitMKTGSep 17, 2010
Invagen PharmsFor profitMKTGApr 20, 2005
MylanFor profitMKTGAug 14, 2006
NovartisFor profitMKTGSep 28, 2005
Prinston IncFor profitMKTGAug 29, 2016
RanbaxyFor profitMKTGApr 23, 2004
SandozFor profitMKTGSep 28, 2005
Sun PharmaceuticalsFor profitMKTGDec 17, 2004
TevaFor profitMKTGNov 25, 2003
Upsher-Smith LaboratoriesFor profitMKTGApr 23, 2004
Watson PharmaceuticalsFor profitMKTGDec 23, 2004